Her2 Negative clinical trials

Explore recruiting her2 negative clinical trials.

Recruiting her2 negative studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Her2 Negative trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

SERENA-2: A Randomised, Open-Label, Parallel-Group, Multicentre Phase 2 Study Comparing the Efficacy and Safety of Oral AZD9833 versus Fulvestrant in Women with Advanced ER-Positive HER2-Negative Breast Cancer

Belgium, Hungary, France, Italy, Portugal, Spain +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

IBCSG 67-22 PREcoopERA: A Window-of-Opportunity trial of giredestrant +/- triptorelin vs. anastrozole + triptorelin in premenopausal patients with ER-positive/HER2-negative early breast cancer.

Spain, Germany, Italy, Sweden, Hungary, Ireland +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A phase 2 study of trifluridine/tipiracil in patients with ER-positive, HER2-negative advanced breast cancer that previously received chemotherapy (BOOG 2019-01 TIBET study)

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

Substantially improving the cure rate of high-risk BRCA1-like breast cancer patients with personalized therapy (SUBITO) - an international randomized phase III trial

Netherlands, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001; TROPION-Breast04)

Bulgaria, Austria, Poland, Germany, Hungary, Spain +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Randomized phase 2 study of Simvastatin in patients with ARID1A mutated advanced gastrooesophageal carcinoma treated with Nivolumab and Oxaliplatin-based chemotherapy as first-line treatment (The ARES trial).

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Her2 Negative trials by city

Her2 Negative in Toronto Her2 Negative in Vancouver Her2 Negative in Montreal Her2 Negative in Calgary Her2 Negative in Edmonton Her2 Negative in Ottawa Her2 Negative in Winnipeg Her2 Negative in Quebec City Her2 Negative in Hamilton Her2 Negative in Kitchener Her2 Negative in London Her2 Negative in Halifax Her2 Negative in New York Her2 Negative in Los Angeles Her2 Negative in Chicago Her2 Negative in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease